A phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab (TPCA) in metastatic esophageal and gastric cancer

Trial Profile

A phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab (TPCA) in metastatic esophageal and gastric cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Docetaxel; Irinotecan
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Planned End Date changed from 1 Dec 2014 to 1 Jun 2016.
    • 07 Aug 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 27 Feb 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top